RxDoctor Payments Data

Amy Thompson, PA

Physician Assistant · Hickory, NCNPI 1306288485

Payments from drug & device makers

$11,230in general payments, 2019–2025

Across 501 payments — averaging $22.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$2K
  • Sanofi$970
  • Regeneron Healthcare Solutions, Inc.$927
  • Pfizer$646
  • Takeda Pharmaceuticals U.S.A., Inc.$615
  • plus $3K from 34 others

What the payments were for

  • Consulting fees$120%
  • Food & beverage$11,218100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,230 in reported general payments places this provider in the 95th percentile of 7,441 physician assistant providers in North Carolina.

See all physician assistant providers in North Carolina

Medicare billing

Part B allowed, 2024
$8,846
Medicare patients
65
Services billed
113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab19$68,503
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,636
Breo ElliptaFluticasone/Vilanterol29$10,980
Spiriva RespimatTiotropium Bromide13$7,072
Wixela InhubFluticasone Propion/Salmeterol22$2,632
Epinephrine12$2,185
Ipratropium Bromide42$1,724
Albuterol Sulfate HfaAlbuterol Sulfate32$838
Ventolin HfaAlbuterol Sulfate11$611
Fluticasone Propionate47$611
Azelastine Hcl21$466
Montelukast Sodium52$314
Triamcinolone Acetonide22$261
Levocetirizine Dihydrochloride31$228
Gabapentin12$214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$2,034$24,61649 claims
Boehringer IngelheimSpiriva Respimat$91$7,07213 claims
Hikma Pharmaceuticals USAEpinephrine$40$2,18512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,441 physician assistant providers in North Carolina.

Other physician assistant in Hickory

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →